Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FCGR2A stimRNA
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
FCGR2A stimRNA is a preclinical megakaryocyte- and platelet-selective naked modified small interfering RNA (siRNA) designed to suppress the expression of the low-affinity IgG receptor FcγRIIA (encoded by the FCGR2A gene). Developed by researchers at Thomas Jefferson University, this therapeutic candidate is being investigated for the prevention and treatment of post-ischemic stroke reperfusion injury. By selectively downregulating platelet FcγRIIA surface expression, FCGR2A stimRNA attenuates FcγRIIA-dependent platelet activation, P-selectin exposure, and αIIbβ3 integrin activation, thereby reducing thrombo-inflammation and cerebral infarction volume without compromising general hemostatic responses to other platelet agonists.
- Other names
- FCGR2A siRNAFCGR-2A siRNAFCGR 2A siRNAFcγRIIA siRNAFcγRIIA stimRNA
02
Targets
BTK (Bruton tyrosine kinase)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)SYK (Spleen Tyrosine Kinase)
Beyond the preview
Go deeper on FCGR2A stimRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FCGR2A stimRNA.